Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1Hbenzo[ d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:............
PLEASE SEE THE SPECIFICATION ATTACHED.
| # | Name | Date |
|---|---|---|
| 1 | 3296-KOLNP-2010-AbandonedLetter.pdf | 2017-10-07 |
| 2 | 3296-KOLNP-2010-FER.pdf | 2017-03-22 |
| 3 | 3296-KOLNP-2010-(05-11-2012)-CORRESPONDENCE.pdf | 2012-11-05 |
| 3 | Form-1.pdf | 2011-10-07 |
| 4 | 3296-KOLNP-2010-(05-11-2012)-FORM-1.pdf | 2012-11-05 |
| 4 | 3296-KOLNP-2010-FORM 18.pdf | 2011-10-07 |
| 5 | 3296-KOLNP-2010-(05-11-2012)-FORM-13.pdf | 2012-11-05 |
| 6 | 3296-KOLNP-2010-(05-11-2012)-FORM-1.pdf | 2012-11-05 |
| 6 | 3296-KOLNP-2010-FORM 18.pdf | 2011-10-07 |
| 7 | 3296-KOLNP-2010-(05-11-2012)-CORRESPONDENCE.pdf | 2012-11-05 |
| 7 | Form-1.pdf | 2011-10-07 |
| 8 | 3296-KOLNP-2010-FER.pdf | 2017-03-22 |
| 9 | 3296-KOLNP-2010-AbandonedLetter.pdf | 2017-10-07 |
| 1 | 3296Searchstrategy_21-03-2017.pdf |